EPAS1 and nonpapillary renal cell carcinoma: In addition, our investigation revealed that ATL-I is capable of reducing the expression of EPAS1 and reversing the resistance to sunitinib, thereby indicating its promising potential as a novel therapeutic agent for the treatment of ccRCC.